Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mathis

Showing results (381-390 of 569) with videos related to

Pageof 57
Sort By:
Biological Psychiatry|March 10, 2009
Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluidTimo Grimmer, Matthias Riemenschneider, Hans Förstl, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 14, 2024
Development of Pyridothiophene Compounds for PET Imaging of α-SynucleinAnna Pees, Junchao Tong, Saritha Birudaraju, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2002
Sequential H(2)(15)O PET studies in baboons: before and after amphetamineJulie C Price, Wayne C Drevets, James Ruszkiewicz, et al.
Neuroimage|August 15, 2006
Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's diseaseScott K Ziolko, Lisa A Weissfeld, William E Klunk, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|March 1, 1991
Diminished glucose transport in Alzheimer's disease: dynamic PET studiesW J Jagust, J P Seab, R H Huesman, et al.
Synapse (New York, N.Y.)|December 8, 2017
An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxineW Gordon Frankle, Brigitte Robertson, Gary Maier, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|April 9, 2019
Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal IndividualsNeelesh K Nadkarni, Dana Tudorascu, Elizabeth Campbell, et al.
Plos One|March 3, 2012
[11C]flumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levelsW Gordon Frankle, Raymond Y Cho, N Scott Mason, et al.
Journal of Computer Assisted Tomography|August 1, 1983
Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucoseR P Friedland, T F Budinger, E Ganz, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 11, 2008
Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjectsW Gordon Frankle, Raymond Y Cho, Rajesh Narendran, et al.
Pageof 57

Showing results (381-390 of 569) with videos related to

Sort By:
Pageof 57
Biological Psychiatry|March 10, 2009
Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluidTimo Grimmer, Matthias Riemenschneider, Hans Förstl, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|February 14, 2024
Development of Pyridothiophene Compounds for PET Imaging of α-SynucleinAnna Pees, Junchao Tong, Saritha Birudaraju, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2002
Sequential H(2)(15)O PET studies in baboons: before and after amphetamineJulie C Price, Wayne C Drevets, James Ruszkiewicz, et al.
Neuroimage|August 15, 2006
Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's diseaseScott K Ziolko, Lisa A Weissfeld, William E Klunk, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|March 1, 1991
Diminished glucose transport in Alzheimer's disease: dynamic PET studiesW J Jagust, J P Seab, R H Huesman, et al.
Synapse (New York, N.Y.)|December 8, 2017
An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxineW Gordon Frankle, Brigitte Robertson, Gary Maier, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|April 9, 2019
Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal IndividualsNeelesh K Nadkarni, Dana Tudorascu, Elizabeth Campbell, et al.
Plos One|March 3, 2012
[11C]flumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levelsW Gordon Frankle, Raymond Y Cho, N Scott Mason, et al.
Journal of Computer Assisted Tomography|August 1, 1983
Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucoseR P Friedland, T F Budinger, E Ganz, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 11, 2008
Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjectsW Gordon Frankle, Raymond Y Cho, Rajesh Narendran, et al.
Pageof 57